Schrodinger Inc Revenue Growth Rates (SDGR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Schrodinger Inc   (NASDAQ: SDGR)
 

SDGR's Revenue Growth by Quarter and Year

Schrodinger Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SDGR/growth
https://api.csimarket.com/api/v1/companies/SDGR/fundamentals
https://api.csimarket.com/api/v1/companies/SDGR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
SDGR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 64.49
2nd Quarter June 58.89
1st Quarter March 58.59
FY 181.97

SDGRs Annual Revenue
Schrodinger Inc 's Revenue in the fiscal year 2025 $ 255.87 millions
Schrodinger Inc 's Revenue in the fiscal year 2024 $ 207.54 millions
Schrodinger Inc 's Revenue in the fiscal year 2023 $ 215.69 millions
Schrodinger Inc 's Revenue in the fiscal year 2022 $ 180.96 millions
Schrodinger Inc 's Revenue in the fiscal year 2021 $ 137.93 millions




SDGR Revenue third quarter 2026 Y/Y Growth Comment
Schrodinger Inc reported Revenue increase of 18.72% year on year in the third quarter 2026, to $ 64.49 millions, this is lower than Schrodinger Inc 's recent average Revenue improvement of 20.08%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 104 other companies have achieved higher Revenue growth. While Schrodinger Inc ' s Revenue growth of 18.72% ranks overall at the positon no. 2231 in the third quarter 2026.


SDGR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.72 %
2nd Quarter June 7.54 %
1st Quarter March -1.61 %
FY   -

Financial Statements
Schrodinger Inc 's third quarter 2026 Revenue $ 64.49 millions SDGR's Income Statement
Schrodinger Inc 's third quarter 2025 Revenue $ 54.32 millions Quarterly SDGR's Income Statement


SDGR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.51 %
2nd Quarter June 0.51 %
1st Quarter March -32.83 %
FY (Year on Year)   -


Back to SDGR Growth rate Comparisons >> Back to SDGR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #326
Overall #2231

Revenue Y/Y Growth Statistics
High Average Low
36.45 % 20.08 % -5.21 %
(Sep 30 2022)   (Mar 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #326
Overall #2231
Revenue Y/Y Growth Statistics
High Average Low
36.45 % 20.08 % -5.21 %
(Sep 30 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Schrodinger Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
160.84 % 10.26 % -51.55 %
(Dec 31 2024)  


SDGR's III. Quarter Q/Q Revenue Comment
Schrodinger Inc achieved in the III. Quarter 2026 below company average Revenue increase of 9.51% quarter on quarter, to $ 64.49 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -0.8% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Revenue quarter on quarter growth. While Schrodinger Inc 's Revenue growth quarter on quarter, overall rank is 1713.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #227
Overall #1713
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #227
Overall #1713
Revenue Q/Q Growth Statistics
High Average Low
160.84 % 10.26 % -51.55 %
(Dec 31 2024)  


SDGR's III. Quarter Q/Q Revenue Comment
Schrodinger Inc achieved in the III. Quarter 2026 below company average Revenue increase of 9.51% quarter on quarter, to $ 64.49 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -0.8% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Revenue quarter on quarter growth. While Schrodinger Inc 's Revenue growth quarter on quarter, overall rank is 1713.


Schrodinger Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 259.03
Y / Y Revenue Growth (TTM) 8.1 %
Year on Year Revenue Growth Overall Ranking # 814
Seqeuential Revenue Change (TTM) 1.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 2231


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Schrodinger Inc 's cumulative twelve months Revenue were $ 259 millions, company would post below average annual Revenue growth of 1.62% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Schrodinger Inc 's Revenue growth from the 58.89% growth in Mar 31 2026.

In the Healthcare sector 169 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 814, from total ranking in previous quarter at 2615.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 170
Overall # 814

Revenue TTM Y/Y Growth Statistics
High Average Low
36.45 %
 20.08 %
-5.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2231
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Schrodinger Inc 's cumulative twelve months Revenue were $ 259 millions, company would post below average annual Revenue growth of -5.21% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Schrodinger Inc 's Revenue growth from the 58.89% growth in Mar 31 2026.

In the Healthcare sector 169 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 814, from total ranking in previous quarter at 2615.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 170
Overall # 814

Revenue TTM Y/Y Growth Statistics
High Average Low
36.45 %
20.08 %
-5.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2231




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SDGR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions


About Schrodinger Inc Revenue Growth Rates (SDGR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Schrodinger Inc (CIK 1490978).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001490978-26-000076
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Schrodinger Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.